BioLight Life Sciences (XTAE:BOLT) Beginning Cash Position: ₪3.98 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:BOLT BioLight Life Sciences Ltd XTAE:BOLT
19 GF Score
Price ₪2.90
! 3 Warning Signs
View Full Analysis

What is BioLight Life Sciences Beginning Cash Position?

BioLight Life Sciences XTAE:BOLT 19 Beginning Cash Position is ₪3.98 Mil as of Jun. 2026. GuruFocus rates XTAE:BOLT with a GF Score™ of 19/100. The stock has 3 warning signs investors should review.

BioLight Life Sciences's Beginning Cash Position for the quarter that ended in Jun. 2026 was ₪3.98 Mil.

BioLight Life Sciences's quarterly Beginning Cash Position declined from Jun. 2025 (₪9.72 Mil) to Dec. 2025 (₪5.73 Mil) and declined from Dec. 2025 (₪5.73 Mil) to Jun. 2026 (₪3.98 Mil).

BioLight Life Sciences's annual Beginning Cash Position declined from Dec. 2023 (₪13.39 Mil) to Dec. 2024 (₪5.28 Mil) but then increased from Dec. 2024 (₪5.28 Mil) to Dec. 2025 (₪9.72 Mil).

BioLight Life Sciences Beginning Cash Position Related Terms

BioLight Life Sciences Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for BioLight Life Sciences's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLight Life Sciences Beginning Cash Position Chart

BioLight Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.99 33.47 13.39 5.28 9.72

BioLight Life Sciences Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.28 1.37 9.72 5.73 3.98
XTAE:BOLT
19GF Score
BioLight Life Sciences Ltd XTAE:BOLT
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLight Life Sciences Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of ₪3.98 Mil mean?
BioLight Life Sciences (XTAE:BOLT) has a Beginning Cash Position of ₪3.98 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on BioLight Life Sciences and its competitors.
Is BioLight Life Sciences' Beginning Cash Position too high?
BioLight Life Sciences' current Beginning Cash Position is ₪3.98 Mil. Overall, BioLight Life Sciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does BioLight Life Sciences' Beginning Cash Position compare to VRTX and REGN?
BioLight Life Sciences' Beginning Cash Position of ₪3.98 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on BioLight Life Sciences and its competitors. BioLight Life Sciences's current Beginning Cash Position is ₪3.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLight Life Sciences stock overvalued right now?
BioLight Life Sciences (XTAE:BOLT) has a current Beginning Cash Position of ₪3.98 Mil. The current Beginning Cash Position is ₪3.98 Mil. BioLight Life Sciences' overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For BioLight Life Sciences (XTAE:BOLT), the current Beginning Cash Position is ₪3.98 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioLight Life Sciences Business Description

Address Aba Hillel Silver 12, 11 floor, Ramat Gan, ISR, 5250606
BioLight Life Sciences Ltd is an emerging ophthalmic company. It is engaged in the discovery, development, and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome and age-related macular degeneration. The firm's products include ioptimate, eye-d technology, and diagnostear. The company has the Eye cluster and the Cancer diagnostics cluster operating segments. It derives the majority of its revenues from the Eye cluster segment.
19GF Score

Get the complete analysis for XTAE:BOLT

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪2.90
Price